Long-chain fatty acid transport protein 6 (SLC27A6)

Long-chain fatty acid transport protein 6 (SLC27A6/FATP6) is a member of the fatty acid transport protein (FATP) family within the solute carrier (SLC27) superfamily[1][2][3]. SLC27A6 functions as both a transporter and an acyl-CoA synthetase, mediating the import and metabolic activation of long-chain and very long-chain fatty acids through the cell membrane, especially in cardiomyocytes where it plays a dominant role in energy homeostasis and contractile function[1][2][3]. It is also implicated in cellular growth, particularly by modulating the lipid requirements for cell cycle progression in non-tumorigenic breast cells[4]. Aberrant expression is linked to metabolic disorder protection (favorable triglyceride and insulin profiles) and, when overexpressed, to tumor progression and aggressiveness in some cancers (e.g., papillary thyroid cancer)[1][4]. Genetic variants associate with features of metabolic and cardiovascular disease, including blood pressure and left ventricular hypertrophy[1]. SLC27A6 may serve as a biomarker for disease risk or progression in these settings. No direct pharmacological inhibitors or approved drugs are available for SLC27A6 specifically; however, theoretical interventions could impact energy metabolism, particularly in the heart[1][2][3][4][5].

Other names

SLC27A6FATP6FACVL2ACSVL2VLCS-H1Very long-chain acyl-CoA synthetase homolog 1Long-chain-fatty-acid--CoA ligaseFatty-acid-Coenzyme A ligase, very long-chain 2Solute carrier family 27 member 6Fatty acid transport protein 6

Not applicable for drugs, as no direct approved modulators are documented for SLC27A6. FATP6, including SLC27A6, would theoretically be inhibited by molecules that block fatty acid uptake or acyl-CoA formation.